In addition, TMEM16A inhibition by T16A-inhA01 and CaCC-inhA01 has been reported to increase responses to EGFR/HER2-targeted therapy in HNSCC cells [110]. This evidence concerns the gene ERBB2 and head and neck squamous cell carcinoma.